Design Therapeutics Inc
NASDAQ:DSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Design Therapeutics Inc
Pre-Tax Income
Design Therapeutics Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Pre-Tax Income
-$50m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-89%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$9.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
42%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
16%
|
|
Design Therapeutics Inc
Glance View
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.
See Also
What is Design Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-50m
USD
Based on the financial report for Dec 31, 2024, Design Therapeutics Inc's Pre-Tax Income amounts to -50m USD.
What is Design Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-89%
Over the last year, the Pre-Tax Income growth was 25%. The average annual Pre-Tax Income growth rates for Design Therapeutics Inc have been -12% over the past three years , -89% over the past five years .
